Oncoproteomics: Trials and tribulations

Zhou, Li; Li, Qifu; Wang, Jiandong; Huang, Canhua; Nice, Edouard C.

doi:10.1002/prca.201500081

Cited by 9 publications

(2 citation statements)

References 175 publications

(215 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MSCs were grown under the standard situation in 6-well plates and treated by reovirus in the different multiplicity of infection (MOI) [ 1 , 5 , 10 ]. The treated MSCs were subjected to apoptosis assay at 24, 48, and 72 h post infection (P.I) using Annexin V-7AAD apoptosis detection kit according to the manufacturer’s instructions (eBioscience, USA, Lot:4,331,154).…”

Section: Methodsmentioning

confidence: 99%

“…The accumulation of genetic alterations may lead to cancer development. Various cancer types were reported as the second cause of deaths worldwide, leading to 9.6 million global mortality [ 1 , 2 ]. Despite the promising advances of existing methods in cancer therapy, these strategies confront some challenges such as low efficiency as well as side effects [ 3 , 4 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

MSCs loaded with oncolytic reovirus: migration and in vivo virus delivery potential for evaluating anti-cancer effect in tumor-bearing C57BL/6 mice

et al. 2021

View full text Add to dashboard Cite

Background and aims Several oncolytic viruses applications have been approved in the clinic or in different phases of clinical trials. However, these methods have some rudimentary problems. Therefore, to enhance the delivery and quality of treatment, considering the advantage of cell carrier-based methods such as Mesenchymal Stem Cells (MSC) have been proposed. This study was designed to evaluate the performance and quality of cancer treatment based on MSCs loaded by oncolytic reovirus in the cancerous C57BL/6 mouse model. Also, we evaluated MSCs migration potency in vitro and in vivo following the oncolytic reovirus infection. Methods C57BL/6 mice were inoculated with TC-1 cell lines and tumors were established in the right flank. Mice were systemically treated with reovirus, MSCs-loaded with reovirus, MSCs, and PBS as a control in separated groups. Effects of infected AD-MSCs with reovirus on tumor growth and penetration in the tumor site were monitored. All groups of mice were monitored for two months in order to therapeutic and anticancer potential. After treatments, tumor size alteration and apoptosis rate, as well as cytokine release pattern was assessed. Results The results of the current study indicated that the effect of reovirus infection on AD-MSCs is not devastating the migration capacity especially in MOI 1 and 5 while intact cells remain. On the other hand, MSCs play an efficient role as a carrier to deliver oncolytic virus into the tumor site in comparison with systemic administration of reovirus alone. Apoptosis intensity relies on viral titration and passing time. Followed by systemic administration, treatment with oncolytic reovirus-infected AD-MSCs and MSCs alone had shown significant inhibition in tumor growth. Also, treatment by reovirus causes an increase in IFN-γ secretion. Conclusion The results of in vitro and in vivo study confirmed the tumor-homing properties of infected AD-MSCs and the significant antitumor activity of this platform. Hence, our results showed that the cell carrier strategy using oncolytic reovirus-loaded AD-MSCs enhanced virus delivery, infiltration, and antitumor activity can be effectively applied in most cancers.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

MSCs loaded with oncolytic reovirus: migration and in vivo virus delivery potential for evaluating anti-cancer effect in tumor-bearing C57BL/6 mice

et al. 2021

View full text Add to dashboard Cite

show abstract

Proteomics and Protein Biomarkers in Cancer Metastasis

Gezici

2023

Handbook of Cancer and Immunology

View full text Add to dashboard Cite

A Selected Reaction Monitoring Mass Spectrometry Protocol for Validation of Proteomic Biomarker Candidates in Studies of Psychiatric Disorders

Reis‐de‐Oliveira

Garcia

Guest

et al. 2017

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

Most biomarker candidates arising from proteomic studies of psychiatric disorders have not progressed for use in clinical studies due to insufficient validation steps. Here we describe a selective reaction monitoring mass spectrometry (SRM-MS) approach that could be used as a follow-up validation tool of proteins identified in blood serum or plasma. This protocol specifically covers the stages of peptide selection and optimization. The increasing application of SRM-MS should enable fast, sensitive, and robust methods with the potential for use in clinical studies involving sampling of serum or plasma. Understanding the molecular mechanisms and identifying potential biomarkers for risk assessment, diagnosis, prognosis, and prediction of drug response goes toward the implementation of translational medicine strategies for improved treatment of patients with psychiatric disorders and other debilitating diseases.

show abstract

Oncoproteomics: Trials and tribulations

Cited by 9 publications

References 175 publications

MSCs loaded with oncolytic reovirus: migration and in vivo virus delivery potential for evaluating anti-cancer effect in tumor-bearing C57BL/6 mice

MSCs loaded with oncolytic reovirus: migration and in vivo virus delivery potential for evaluating anti-cancer effect in tumor-bearing C57BL/6 mice

Proteomics and Protein Biomarkers in Cancer Metastasis

A Selected Reaction Monitoring Mass Spectrometry Protocol for Validation of Proteomic Biomarker Candidates in Studies of Psychiatric Disorders

Contact Info

Product

Resources

About